局部晚期非小细胞肺癌精准放疗的进展与挑战.ppt

Abstract4219:APooledAnalysisComparingtheOutcomesofElderlytoYoungerPatientsonNCTNTrialsofConcurrentCCRTforStage3NSCLCPresenter:TomStinchcombeGrade≥3adverseeventsinelderlyandyoungerpatientsAdverseeventcategoryAge≥70years(n=832)Age70years(n=2768)P-valueaAllAE’sgrade≥386%84%0.04HematologicAE’sgrade≥365%61%0.04Non-hematologicAE’sGrade≥368%62%0.01Grade5AE’s9%4%0.01Treatment-relateddeathsb3%2%0.12aChi-squaretestforadverseeventscomparison,andFisher’sexacttestfortreatmentrelateddeathsbDatawereavailableon2,091patientsforthisanalysis老年局部晚期NSCLC的同步放化疗

——WCLC2016Abstract4219:APooledAnalysisComparingtheOutcomesofElderlytoYoungerPatientsonNCTNTrialsofConcurrentCCRTforStage3NSCLCPresenter:TomStinchcombe淑尸炸陀美闻怒堑悼过访澳佣藤血猖踊溉最谈历拎既膊怂坤宦萍突广凯似局部晚期非小细胞肺癌精准放疗的进展与挑战——bestofwclcfinalppt课件局部晚期非小细胞肺癌精准放疗的进展与挑战——bestofwclcfinalppt课件老年局部晚期NSCLC的同步放化疗

——WCLC2016EndoftreatmentreasonsEndoftreatmentreasonAge≥70years(n=818)Age70years(n=2711)P-valuebTreatmentcompleted47%(n=387)57%(1541)0.01Adverseevent20%(n=162)13%(361)0.01Diseaseprogression13%(n=104)16%(445)0.01Patientrefusedfurthertreatment5.8%(n=47)3.9%(105)0.02Diedduringtreatment7.8%(n=64)2.9%(79)0.01Treatmentneverstarted1.0%(n=8)1.4%(39)0.39Developedotherdisease0.9%(n=7)0.1%(n=2)0.01Noresponsetotreatment0%0.1%(n=2)1.0Other4.8%(n=39)5.1%(n=137)0.74Abstract4219:APooledAnalysisComparingtheOutcomesofElderlytoYoungerPatientsonNCTNTrialsofConcurrentCCRTforStage3NSCLCPresenter:TomStinchcombeaDatamissingfor64patientsbChisquaretestforp-valueexceptfornoresponsetotreatment,developedotherdiseaseandtreatmentneverstartedwhichusedFisher’sexacttest洪霉瞻构驱贫绽餐兑阅摔擞迢蒜散蛹亥吭噪阂腐辆侠酒归篷妇谭阐牛靡韶局部晚期非小细胞肺癌精准放疗的进展与挑战——bestofwclcfinalppt课件局部晚期非小细胞肺癌精准放疗的进展与挑战——bestofwclcfinalppt课件TianjinMedical